title: Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
abstract: OBJECTIVE
  This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Chemotherapy-naïve patients with stage III, stage IV, or recurrent NSCLC age ≥ 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m(2) on day 1, every 3 weeks, or docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on days 1, 8, and 15, every 4 weeks. The primary end point was overall survival (OS).
  
  
  RESULTS
  In the first interim analysis, OS of the doublet arm was inferior to that of the monotherapy arm (hazard ratio [HR], 1.56; 95% CI, 0.98 to 2.49), and the predictive probability that the doublet arm would be statistically superior to the monotherapy arm on final analysis was 0.996%, which led to early study termination. In total, 276 patients with a median age of 76 years (range, 70 to 87 years) were enrolled. At the updated analysis, the median survival time was 14.8 months for the monotherapy arm and 13.3 months for the doublet arm (HR, 1.18; 95% CI, 0.83 to 1.69). The rates of grade ≥ 3 neutropenia and febrile neutropenia were higher in the monotherapy arm, and those of anorexia and hyponatremia were higher in the doublet arm.
  
  
  CONCLUSIONS
  This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients.
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan. t-abe@niigata-cc.jp.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Abe
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Takeda
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Ohe
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Shinzoh
authors.initials: S
authors.lastname: Kudoh
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Yukito
authors.initials: Y
authors.lastname: Ichinose
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Okamoto
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Yamamoto
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Yoshioka
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Minato
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Sawa
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Iwamoto
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Saka
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Junki
authors.initials: J
authors.lastname: Mizusawa
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Taro
authors.initials: T
authors.lastname: Shibata
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nakamura
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ando
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Yokoyama
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakagawa
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Nagahiro
authors.initials: N
authors.lastname: Saijo
authors.affiliation: Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Tomohide
authors.initials: T
authors.lastname: Tamura
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011788:Quality of Life; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin